Entia Biosciences, Inc. (ERGO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEntia Biosciences, Inc. (ERGO) trades at $0.001. Entia Biosciences, Inc. (ERGO) is a biotechnology company focused on developing dietary supplements and medical foods. Based in Sherwood, Oregon, it specializes in natural formulations for various health applications. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ERGO: ERGO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Entia Biosciences, Inc. (ERGO) Healthcare & Pipeline Overview
Entia Biosciences, Inc. is a biotechnology firm dedicated to the development and distribution of innovative dietary supplements and medical foods, leveraging unique formulations to address chronic health conditions and enhance well-being.
What Is the Investment Thesis for ERGO?
Entia Biosciences, Inc. presents a unique investment thesis driven by its innovative product portfolio and strategic focus on health and wellness. The company’s gross margin stands at 65.5%, indicating strong pricing power and operational efficiency. With ongoing development of products targeting chronic kidney disease, Entia is positioned to capture a growing market segment. The global dietary supplements market is projected to reach approximately $230 billion by 2027, providing a substantial growth opportunity for Entia. The company’s focus on e-commerce and direct-to-consumer sales enhances its market reach and customer engagement, potentially driving revenue growth in the coming years. However, the company must navigate its negative profit margin of -554.7% and address operational challenges to achieve sustainable profitability.
Based on FMP financials and quantitative analysis
ERGO Key Highlights
Gross margin of 65.5% indicates strong operational efficiency compared to industry averages.
- Market cap currently stands at $0.00B, reflecting its early-stage development status.
- Negative profit margin of -554.7% highlights the need for improved cost management.
- The company employs a lean workforce of 6, allowing for agile decision-making.
- Beta of 38.17 suggests high volatility, which may appeal to risk-tolerant investors.
Who Are ERGO's Competitors?
ERGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NTRB Nutriband Inc. | $7.28 | -1.09% | $88.5M | — |
| VYGR Voyager Therapeutics, Inc. | $2.45 | -8.41% | $148M | — |
| AMRN Amarin Corporation plc | $12.35 | -2.91% | $255M | — |
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ERGO's Key Strengths?
Innovative product formulations with potential health benefits.
- Strong gross margins indicating operational efficiency.
- Direct-to-consumer sales model enhancing customer engagement.
What Are ERGO's Weaknesses?
High volatility reflected in the beta of 38.17.
- Negative profit margin indicating operational challenges.
- Limited workforce may restrict growth capabilities.
What Are the Key Risks for ERGO?
Regulatory hurdles in product approvals could delay market entry.
- High operational costs leading to negative profit margins.
- Market competition may impact pricing and sales strategies.
What Threats Does ERGO Face?
- Intense competition in the biotechnology and nutraceutical sectors.
- Regulatory challenges related to product approvals.
- Market volatility affecting consumer spending on health products.
What Are ERGO's Competitive Advantages?
- Unique formulations backed by scientific research.
- Strong focus on e-commerce providing direct consumer access.
- Niche market positioning in dietary supplements and medical foods.
- Small team allows for agile decision-making and innovation.
What Does ERGO Do?
Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. Originally known as Total Nutraceutical Solutions, Inc., the company rebranded in January 2012 to reflect its focus on biosciences. Entia specializes in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods. Its portfolio includes proprietary formulations such as ErgoD2, a pharmaceutical-grade organic compound derived from whole foods, which is rich in micro-nutrients. The company also offers L-Ergothioneine, a naturally occurring amino acid recognized for its antioxidant properties, alongside vitamin D. Entia is actively developing products aimed at chronic kidney disease and other health conditions, as well as cosmeceuticals marketed under the GROH brand. The company utilizes e-commerce channels for direct consumer sales, employing strategies such as email marketing and social media outreach to promote its products. With a small team of six employees, Entia Biosciences is positioned in a niche market, emphasizing the scientific evaluation and marketing of its innovative health solutions.
What Products and Services Does ERGO Offer?
- Develops dietary supplements and nutraceuticals for health enhancement.
- Produces medical foods targeting specific health conditions.
- Markets proprietary formulations like ErgoD2 and L-Ergothioneine.
- Offers cosmeceuticals under the GROH brand for beauty applications.
- Utilizes e-commerce channels for direct-to-consumer sales.
- Engages in scientific evaluation and marketing of natural health products.
How Does ERGO Make Money?
- Generates revenue through the sale of dietary supplements and medical foods.
- Utilizes e-commerce platforms to reach consumers directly.
- Employs digital marketing strategies for product promotion.
- Focuses on innovative product development to meet market demands.
What Industry Does ERGO Operate In?
The biotechnology industry is experiencing significant growth, driven by increasing health awareness and demand for innovative health solutions. The global dietary supplements market is expected to grow at a CAGR of 8.2%, reaching $230 billion by 2027. Entia Biosciences, Inc. operates in a competitive landscape with various players focusing on nutraceuticals and medical foods. The company's unique formulations and emphasis on scientific evaluation provide a competitive edge in a market characterized by rapid innovation and evolving consumer preferences.
Who Are ERGO's Key Customers?
- Health-conscious consumers seeking dietary supplements.
- Patients with chronic conditions requiring specialized medical foods.
- Beauty enthusiasts interested in cosmeceuticals.
- E-commerce shoppers looking for convenient health solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Entia Biosciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
Return on equity for Entia Biosciences, Inc. stands at 106.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Entia Biosciences, Inc. operates in the Healthcare sector. It is headquartered in Sherwood, US. The company is led by CEO Timothy A. Timmins. ERGO has traded publicly since 2008.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
ERGO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ERGO Latest News
No recent news available for ERGO.
ERGO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ERGO.
Price Targets
Wall Street price target analysis for ERGO.
ERGO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ERGO; grades run from A+ (80-100) to F (below 30).
Leadership: Timothy A. Timmins
CEO
Timothy A. Timmins has extensive experience in the healthcare and biotechnology sectors. He has been instrumental in guiding the strategic direction of Entia Biosciences since its inception in 2007. Timmins holds a degree in business administration and has a background in product development and marketing within the health and wellness industry.
Track Record: Under Timmins' leadership, Entia has successfully transitioned from Total Nutraceutical Solutions to a focused biotechnology firm. He has overseen the development of key product lines and the establishment of e-commerce sales channels, positioning the company for future growth.
ERGO OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically has less stringent reporting requirements and may have lower visibility among investors compared to NASDAQ or NYSE-listed companies.
- OTC Tier: OTC Other
- Limited financial disclosure may hinder transparency.
- Potential for low trading volume affecting liquidity.
- Higher volatility associated with OTC stocks.
- Verify the company's product pipeline and development status.
- Assess the management team's experience and track record.
- Review any available financial statements or reports.
- Investigate regulatory compliance and approval processes.
- Evaluate market trends and competitive landscape.
- Established company history since 2007.
- Rebranding to Entia Biosciences reflects strategic focus.
- Innovative product offerings backed by scientific evaluation.
Entia Biosciences, Inc. Healthcare Stock: Key Questions Answered
How does Entia Biosciences, Inc. navigate regulatory approval processes?
Entia Biosciences, Inc. must adhere to stringent regulatory standards set by the FDA for dietary supplements and medical foods. The company engages in thorough scientific evaluation and documentation of its product formulations to ensure compliance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available due to OTC classification.